- Email: [email protected]
4758656 Novel human interferongamma polypeptide derivative
84
PATENT ABSTRACTS
crosslinked fibrin derivative including the steps of: (i) obtaining a crosslinked fibrin derivative or extract containing same; and (ii) forming an antibody to said derivative or extract by cloning antibody producing cells from an animal having been administered thereto said derivative or extract. A screening assay for use in the abovementioned method which includes the steps of: (A) coating a surface with an antigen selected from a (i) crosslinked fibrin derivative; (ii) extract containing said derivative; or (iii) fibrinogen degradation product. (B) contacting said antigen with a monoclonal antibody derived from crosslinked fibrin derivative; and (C) subjecting the complex formed in step (A) to a signal amplification step and an assay procedure for detection of the presence of a crosslinked fibrin derivative in an animal body fluid including the steps of: (i) contacting a monoclonal antibody prepared from a crosslinked fibrin derivative with a fluid sample suspected of containing an antigen derived from a crosslinked fibrin derivative or comprising a crosslinked fibrin derivative per se; and (ii) subjecting the complex formed in step (i) to a signal amplification step are also provided.
plasmid wherein a DNA fragment coding for said polypeptide is incorporated and a process for producing the derivative of human interferon- gamma polypeptide using a microorganism containing said plasmid.
4760017 ARABINONUCLEIC ACID PROBES FOR DNA[RNA ASSAYS Randy M McCormick assigned to E I Du Pont de Nemours and Company A novel nucleic acid, arabinonucleic acid, is provided as a probe in nucleic acid assays. The arabinose moiety of the probe can be detected with anti-arabinose antibody-label conjugates.
4760022 4758572 ANTIVIRAL COMBINATIONS Thomas Spector, Devron R Averett, Donald J Nelson assigned to Burroughs Wellcome Co Synergistic combinations of nucleoside analogues, which are converted to viral DNA polymerase inhibitors through the action of at least one virus-induced enzyme, and thiosemicarbazone ribonucleotide reductase inhibitors are especially useful in combatting herpes virus infections.
4758656 NOVEL HUMAN INTERFERONGAMMA POLYPEPTIDE DERIVATIVE Seiga Itoh, Susumu Sekine, Akiko Saito, Moriyuki Sato, Sagamihara, Japan assigned to Kyowa Hakko Kogyo Co Ltd Disclosed is a novel derivative of human interferon- gamma polypeptide, a recombinant
STABILIZED PLASMIDS Soen Molin, Kenn A Gerdes, Holte, Denmark assigned to A/S Alfred Benzon Plasmids which are in themselves unstably inherited or which have become unstable due to the insertion of a DNA fragment comprising one or more genes not naturally related to the plasmid are stablized by means of a partitioning function exerted by a par region, especially a plasmid RI par region, inserted into the plasmid on a DNA fragment which may be the length of the wild-type R1 EcoRl-. A fragment, but which is preferably shorter than this fragment, and which may comprise the R 1 par region A, the R 1 par region B or both these R1 par regions. The stabilization obtained for several different types of plasmid, especially by employing both R 1 par regions, approaches the stability level of wildtype plasmids, i.e. they typically have a frequency of loss of less than 5"1031 6 per cell per generation. Such stabilized plasmids are useful in large-scale production of gene products as no particular bacterial strains or mutants are needed to secure plasmid maintenance, and as is not necessary to employ a specific composition of the nutrient medium in which the host cells are grown in order to prevent loss of the plasmid from the bacterial population.
PATENT ABSTRACTS
crosslinked fibrin derivative including the steps of: (i) obtaining a crosslinked fibrin derivative or extract containing same; and (ii) forming an antibody to said derivative or extract by cloning antibody producing cells from an animal having been administered thereto said derivative or extract. A screening assay for use in the abovementioned method which includes the steps of: (A) coating a surface with an antigen selected from a (i) crosslinked fibrin derivative; (ii) extract containing said derivative; or (iii) fibrinogen degradation product. (B) contacting said antigen with a monoclonal antibody derived from crosslinked fibrin derivative; and (C) subjecting the complex formed in step (A) to a signal amplification step and an assay procedure for detection of the presence of a crosslinked fibrin derivative in an animal body fluid including the steps of: (i) contacting a monoclonal antibody prepared from a crosslinked fibrin derivative with a fluid sample suspected of containing an antigen derived from a crosslinked fibrin derivative or comprising a crosslinked fibrin derivative per se; and (ii) subjecting the complex formed in step (i) to a signal amplification step are also provided.
plasmid wherein a DNA fragment coding for said polypeptide is incorporated and a process for producing the derivative of human interferon- gamma polypeptide using a microorganism containing said plasmid.
4760017 ARABINONUCLEIC ACID PROBES FOR DNA[RNA ASSAYS Randy M McCormick assigned to E I Du Pont de Nemours and Company A novel nucleic acid, arabinonucleic acid, is provided as a probe in nucleic acid assays. The arabinose moiety of the probe can be detected with anti-arabinose antibody-label conjugates.
4760022 4758572 ANTIVIRAL COMBINATIONS Thomas Spector, Devron R Averett, Donald J Nelson assigned to Burroughs Wellcome Co Synergistic combinations of nucleoside analogues, which are converted to viral DNA polymerase inhibitors through the action of at least one virus-induced enzyme, and thiosemicarbazone ribonucleotide reductase inhibitors are especially useful in combatting herpes virus infections.
4758656 NOVEL HUMAN INTERFERONGAMMA POLYPEPTIDE DERIVATIVE Seiga Itoh, Susumu Sekine, Akiko Saito, Moriyuki Sato, Sagamihara, Japan assigned to Kyowa Hakko Kogyo Co Ltd Disclosed is a novel derivative of human interferon- gamma polypeptide, a recombinant
STABILIZED PLASMIDS Soen Molin, Kenn A Gerdes, Holte, Denmark assigned to A/S Alfred Benzon Plasmids which are in themselves unstably inherited or which have become unstable due to the insertion of a DNA fragment comprising one or more genes not naturally related to the plasmid are stablized by means of a partitioning function exerted by a par region, especially a plasmid RI par region, inserted into the plasmid on a DNA fragment which may be the length of the wild-type R1 EcoRl-. A fragment, but which is preferably shorter than this fragment, and which may comprise the R 1 par region A, the R 1 par region B or both these R1 par regions. The stabilization obtained for several different types of plasmid, especially by employing both R 1 par regions, approaches the stability level of wildtype plasmids, i.e. they typically have a frequency of loss of less than 5"1031 6 per cell per generation. Such stabilized plasmids are useful in large-scale production of gene products as no particular bacterial strains or mutants are needed to secure plasmid maintenance, and as is not necessary to employ a specific composition of the nutrient medium in which the host cells are grown in order to prevent loss of the plasmid from the bacterial population.